about
Development of Liposomal Ciprofloxacin to Treat Lung InfectionsAnimal models for Francisella tularensis and Burkholderia species: scientific and regulatory gaps toward approval of antibiotics under the FDA Animal RuleNew therapeutic approaches for treatment of tularaemia: a reviewStructural and Enzymatic Analyses Reveal the Binding Mode of a Novel Series of Francisella tularensis Enoyl Reductase (FabI) InhibitorsComparative genomics reveals multiple pathways to mutualism for tick-borne pathogensToll-like receptor 3 agonist protection against experimental Francisella tularensis respiratory tract infectionLiposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4.Whole-genome immunoinformatic analysis of F. tularensis: predicted CTL epitopes clustered in hotspots are prone to elicit a T-cell response.Discovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matchingBioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus).Clusters versus affinity-based approaches in F. tularensis whole genome search of CTL epitopes.Metabolism-directed structure optimization of benzimidazole-based Francisella tularensis enoyl-reductase (FabI) inhibitors.A spontaneous mutation in kdsD, a biosynthesis gene for 3 Deoxy-D-manno-Octulosonic Acid, occurred in a ciprofloxacin resistant strain of Francisella tularensis and caused a high level of attenuation in murine models of tularemia.Evaluating thermodynamic integration performance of the new amber molecular dynamics package and assess potential halogen bonds of enoyl-ACP reductase (FabI) benzimidazole inhibitors.Tularemia vaccine development: paralysis or progress?Treatment of tularemia in pregnant woman, FranceIdentification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS.Sensitive Detection of Francisella tularensis Directly from Whole Blood by Use of the GeneXpert System.A new dye uptake assay to test the activity of antibiotics against intracellular Francisella tularensis.The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy.Engineered nanoconstructs for the multiplexed and sensitive detection of high-risk pathogens.Control of intracellular Francisella tularensis by different cell types and the role of nitric oxide.Characterization of a Francisella tularensis-Caenorhabditis elegans Pathosystem for the Evaluation of Therapeutic Compounds.Unilateral acute dacryocystitis associated with oculoglandular tularemia: a case report.Unusual bacterial infections and the pleura.Tularemia in central Anatolia.Francisella tularensis as a potential agent of bioterrorism?Evaluation of In-House and Commercial Serological Tests for Diagnosis of Human Tularemia.Human tularemia in France, 2006-2010.
P2860
Q26764772-5C667B54-C41A-4DA1-BC16-F051AAD6B2C6Q26859041-8B2257C7-74D6-47B9-8D84-DB63DFA6E827Q27027375-94BE4513-26E4-48EB-90B9-F11A8ED0A406Q27679331-7EB0A795-37B6-49DF-868F-0D19F5C6FFB0Q28831425-2E829FC4-098C-4BBA-B7A7-D8236E8227DEQ33768930-48DB8DF8-25AC-426E-83C2-124DED720DECQ33797873-9FC94B0C-7B81-461F-BB80-FA74B3F58056Q33916280-A46C3FC4-14BC-4064-9EC0-7E792618D74DQ34078440-F0089BF7-E142-4B70-A4F9-DF4D1E38B090Q34108623-088B4C7D-D853-4E47-8A1C-28EBF51C5E2BQ34260154-EF019CAE-A350-4D1E-988D-BF39CDDEF047Q35166429-58885949-A26F-4CC0-BBAF-1C5F1167F4C7Q36318241-8039175E-21D2-4B1F-918E-DE5410E31AE5Q36625958-25230108-ABB4-45D3-8A17-1A9EAE5C851CQ36908692-AE31AAD1-0A4E-4E4B-AFAB-DFA4D74B2A47Q37020568-035E18CE-D93C-4637-BA18-E582C9766580Q37258244-C4D8B699-49C2-4074-977C-826D447EAD8AQ37581895-A1FD181A-BD79-411F-A362-3594A3828621Q37642305-FB0A1B56-19C9-4DC5-907F-9443560DE848Q38226279-E12A8AFF-1FA8-45D9-9CAD-D685DE3FC9A8Q38953999-1B5F7D85-1BC8-4110-9628-893CB0EB5D6AQ38961855-F9801CC0-3BFC-43F3-95F4-4EC369B1EEB4Q40157296-DF4BD4C1-FC2C-4536-B99B-2D266491852AQ40255938-74F9B994-F1A9-4703-93A2-E47A884EEB44Q40274483-380A8E21-EC08-47AF-AA2D-438B1A45465BQ42288727-D40B0B56-7A7C-43B8-B04D-5CE52678F1FFQ44899004-55463B38-B9EC-4FC9-9ADC-45419D05B074Q47222704-F26D2E1A-284D-4EE4-A12F-C1FDE40615E9Q54343719-7222A6F6-CFB8-4A6C-9B02-F52EF5CA605B
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Tularemia: current diagnosis and treatment options.
@ast
Tularemia: current diagnosis and treatment options.
@en
Tularemia: current diagnosis and treatment options.
@nl
type
label
Tularemia: current diagnosis and treatment options.
@ast
Tularemia: current diagnosis and treatment options.
@en
Tularemia: current diagnosis and treatment options.
@nl
prefLabel
Tularemia: current diagnosis and treatment options.
@ast
Tularemia: current diagnosis and treatment options.
@en
Tularemia: current diagnosis and treatment options.
@nl
P2860
P356
P1476
Tularemia: current diagnosis and treatment options.
@en
P2093
Andrew J H Simpson
Matthew J Hepburn
P2860
P304
P356
10.1586/14787210.6.2.231
P577
2008-04-01T00:00:00Z